Overview

Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer

Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the safety of injections prepared from donor blood cells fused to a patient's own tumor cells which are then used to treat advanced (Stage IV) kidney cancer (renal cell carcinoma or RCC). The study will also explore the effect the injections have on the size of the tumor and the response in the patient's immune system following administration.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company